臨床泌尿器科63巻10号

2009年09月発行

綜説

前立腺癌造骨性骨転移の成立・進展のメカニズム

著者： 米納浩幸¹ 斎藤誠一¹

所属機関： ¹琉球大学医学部器官病態医科学講座泌尿器科学分野

ページ範囲：P.759 - P.769

文献概要

要旨　多くの癌がほとんど溶骨性骨転移をきたすのに対して，前立腺癌では造骨性骨転移が高率に起こることから，前立腺癌は特異的な骨形成促進機構を有するものと考えられている。前立腺癌の腫瘍マーカーとして用いられている前立腺特異抗原は自身のセリンプロテアーゼ活性により骨芽細胞の増殖促進ならびに破骨細胞の抑制を引き起こす。この結果として，骨代謝は骨形成に極めて強く傾くため特徴的な造骨性変化が生じる。また，骨内に侵入した癌細胞は自身の生存，増殖を容易にするために骨の生物学的環境を変えようとする。よって，骨転移を抑制するためには癌細胞と骨環境の相互関連を遮断する手段が要求される。

参考文献

1）Abrams HL, Spiro R and Goldstein N：Metastases in carcinoma：analysis of 1000 autopsied cases. Cancer 3：74-85, 1950

2）Koutsilieris M：Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13：443-449, 1993

3）Ramaswamy S, Ross KN, Lander ES, et al：A molecular signature of metastasis in primary solid tumors. Nat Genet 33：49-54, 2003

4）Hauschka PV, Mavrakos AE, Iafrati MD, et al：Growth factors in bone matrix：isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261：12665-12674, 1986

5）Kaplan RN, Riba RD, Zacharoulis S, et al：VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438：820-827, 2005

6）Shiozawa Y, Havens AM, Pienta KJ, et al：The bone marrow niche：habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22：941-950, 2008

7）Finak G, Bertos N, Pepin F, et al：Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14：518-527, 2008

to invasive breast carcinoma transition. Cancer Cell 13：394-406, 2008

9）Yonou H, Ochiai A, Goya M, et al：Intraosseous growth of human prostate cancer in implanted adult human bone：relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 58：406-413, 2004

10）Pecherstorfer M, Zimmer-Roth I, Schilling T, et al：The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80：97-103, 1995

11）Garnero P, Buchs N, Zekri J, et al：Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82：858-864, 2000

12）Saad F, Gleason DM, Murray R, et al：A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94：1458-1468, 2002

13）Heidenreich A：Bisphosphonates in the management of metastatic prostate cancer. Oncology 65（Suppl 1）：5-11, 2003

14）Yonou H, Kanomata N, Goya M, et al：Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63：2096-2102, 2003

15）Iwamura M, di Sant'Agnese PA, Wu G, et al：Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 53：1724-1726, 1993

16）Cramer SD, Peehl DM, Edgar MG, et al：Parathyroid hormone-related protein（PTH-rP）is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 29：20-29, 1996

17）Iwamura M, Abrahamson P, Schoen S, et al：Parathyroid hormone-related protein：a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43：675-679, 1994

18）Peehl DM, Edgar MG, Cramer SD, et al：Parathyroid hormone-related protein is not an autocrine growth factor for normal prostate epithelial cells. Prostate 31：47-52, 1997

19）Stewart AF：PTH-rP（1-36）as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19：303-306, 1996

20）Ono K, Akatsu T, Murakami T, et al：Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17：774-781, 2002

21）Yoneda T, Sasaki A, Dunstan C, et al：Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99：2509-2517, 1997

22）Goltzman D：Mechanisms of the development of osteoblastic metastases. Cancer 80（8 Suppl）：1581-1587, 1997

23）Peehl DM, Cohen P and Rosenfeld RG：The insulin-like growth factor system in the prostate. World J Urol 13：306-311, 1995

24）Cohen P, Peehl DM, Graves HC, et al：Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142：407-415, 1994

25）Maeda H, Yonou H, Yano K, et al：Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5. Biochem Biophys Res Commun 381：311-316, 2009

26）Goya M, Miyamoto S, Nagai K, et al：Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64：6252-6258, 2004

27）Morton DM and Barrack ER：Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55：2596-2602, 1995

28）Shariat SF, Shalev M, Menesses-Diaz A, et al：Preoperative plasma levels of transforming growth factor beta（1）〔TGF-beta（1）〕strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19：2856-2864, 2001

29）Guise TA and Mundy GR：Cancer and bone. Endocr Rev 19：18-54, 1998

30）Harris SE, Harris MA, Mahy P, et al：Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24：204-211, 1994

31）Bentley H, Hamdy FC, Hart KA, et al：Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66：1159-1163, 1992

32）George D：Platelet-derived growth factor receptors：a therapeutic target in solid tumors. Semin Oncol 28（5 Suppl 17）：27-33, 2001

by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155：1271-1279, 1999

34）Uehara H, Kim SJ, Karashima T, et al：Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95：458-470, 2003

35）Nelson JB, Hedican SP, George DJ, et al：Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1：944-949, 1995

36）Granchi S, Brocchi S, Bonaccorsi L, et al：Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49：267-277, 2001

37）Kuriyama M, Wang MC, Lee CI, et al：Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41：3874-3876, 1981

38）Killian CS, Corral DA, Kawinski E, et al：Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192：940-947, 1993

39）Oesterling JE：Using PSA to eliminate the staging radionuclide bone scan. Urol Clin North Am 20：705-711, 1993

40）Doherty A, Smith G, Banks L, et al：Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer：implications for paracrine growth. J Pathol 188：278-281, 1999

41）Yonou H, Aoyagi Y, Kanomata N, et al：Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 289：1082-1087, 2001

42）Goya M, Ishii G, Miyamoto S, et al：Prostate-specific antigen induces apoptosis of osteoclast precursors：potential role in osteoblastic bone metastases of prostate cancer. Prostate 66：1573-1584, 2006

43）Fleisch H：Bisphosphonates in osteoporosis. Eur Spine J 12（Suppl 2）：S142-146, 2003

44）Saad F, Gleason DM, Murray R, et al：Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96：879-882, 2004

45）Yonou H, Ochiai A, Ashimine S, et al：The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Prostate 67：999-1009, 2007

46）Stearns ME and Wang M：Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 16：116-131, 1996

47）Michigami T, Hiraga T, Williams PJ, et al：The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75：249-258, 2002

48）Berenson JR：Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10：52-62, 2005

49）Migliorati CA, Schubert MM, Peterson DE, et al：Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone：an emerging oral complication of supportive cancer therapy. Cancer 104：83-93, 2005

50）Durie BG, Katz M and Crowley J：Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353：99-102, 2005

51）Simonet WS, Lacey DL, Dunstan CR, et al：Osteoprotegerin：a novel secreted protein involved in the regulation of bone density. Cell 89：309-319, 1997

52）Muraoka RS, Dumont N, Ritter CA, et al：Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109：1551-1559, 2002

53）Yang YA, Dukhanina O, Tang B, et al：Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109：1607-1615, 2002